Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9804758 | 0.86 | CYP2D6 (0.31) | CYP2D6HRH1KCNH2JAK2JAK1 | |
| SCHEMBL9804779 | 0.80 | CCR1 (0.36) | CTDSP1 | |
| SCHEMBL9804637 | 0.80 | CTDSP1 (0.35) | CTDSP1CYP2D6 | |
| SCHEMBL10405751 | 0.79 | CYP3A4 (0.39) | CYP2D6KCNH2 | |
| SCHEMBL9804704 | 0.78 | KDM4E (0.34) | CYP2D6HRH1KCNH2 | |
| SCHEMBL9804854 | 0.77 | CASP1 (0.32) | CTDSP1 | |
| SCHEMBL28149857 | 0.75 | CYP2D6 (0.35) | CTDSP1CYP2D6HRH1KCNH2 | |
| SCHEMBL9804906 | 0.74 | CCR1 (0.34) | — | |
| SCHEMBL9804705 | 0.74 | CYP19A1 (0.39) | — | |
| SCHEMBL10466334 | 0.73 | CASP1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0276920-B1 | (2-CYANO-2-(PHENYL OR NAPHTHYL)-2-SUBSTITUTED-ETHYL) PYRAZINES, PYRIMIDINES AND PYRIDAZINES | ROHM AND HAAS COMPANY (US) | 1991-04-03 | — | — | EP | disclosed |
| EP-0276920-A1 | (2-Cyano-2-(phenyl or naphthyl)-2-substituted-ethyl) pyrazines, pyrimidines and pyridazines | ROHM AND HAAS COMPANY (US) | 1988-08-03 | — | — | EP | disclosed |